about
Targets, models and challenges in osteoarthritis researchMeta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22Optimized alkylated cyclodextrin polysulphates with reduced risks on thromboembolic accidents improve osteoarthritic chondrocyte metabolism.Forced expiration measurements in mouse models of obstructive and restrictive lung diseases.DOT1L safeguards cartilage homeostasis and protects against osteoarthritis.CD248 facilitates tumor growth via its cytoplasmic domain.Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets.Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography.Etoricoxib and the treatment of ankylosing spondylitis.The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis.Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand.Genome-wide association and functional studies identify a role for IGFBP3 in hip osteoarthritis.Longitudinal in vivo microcomputed tomography of mouse lungs: No evidence for radiotoxicity.Aberrant Calreticulin Expression in Articular Cartilage of Dio2 Deficient Mice.Tight regulation of wingless-type signaling in the articular cartilage - subchondral bone biomechanical unit: transcriptomics in Frzb-knockout miceInsulin-Like Growth Factor I Does Not Drive New Bone Formation in Experimental Arthritis.Animal models of spondyloarthritis.Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volumeMechanisms of pathologic new bone formation.Contemporary concepts of inflammation, damage and repair in rheumatic diseases.Translation of clinical problems in osteoarthritis into pathophysiological research goalsWNT Signaling in osteoarthritis and osteoporosis: what is the biological significance for the clinician?Bone morphogenetic protein signaling and arthritis.Osteoporosis: a paradox in ankylosing spondylitis.The role of bone morphogenetic proteins in ankylosing spondylitis.The pathogenesis of pulmonary fibrosis: a moving target.The influence of ageing on the development and management of rheumatoid arthritis.The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.Bone formation in axial spondyloarthritis.Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus.Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements.Fibrogenesis, novel lessons from animal models.Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis.International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphosEuropean League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Microtrauma: no longer to be ignored in spondyloarthritis?Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Mechanisms, impact and prevention of pathological bone regeneration in spondyloarthritis.Secreted Frizzled-related protein 3 (sFRP3)-mediated suppression of interleukin-6 receptor release by A disintegrin and metalloprotease 17 (ADAM17) is abrogated in the osteoarthritis-associated rare double variant of sFRP3.
P50
Q26850147-E81AB923-5F6B-459F-A1AB-A4339665D578Q29417079-610AF205-6804-48A3-8B9F-14D09588C3E1Q33394283-A19D2BD3-3DF0-4851-833F-7AABD95C954CQ33815273-BC55071C-E10E-41BA-A8E5-2E7A11349CCFQ33827165-05D935AA-E57A-48F9-ABC6-63861121B71BQ33891662-D413AEF3-EDF8-44D0-9567-EE8C70CC43D8Q34187070-537645AF-C26A-47FD-B3A5-B3623E29FBA7Q34389324-90A81719-4B84-4BB4-A284-1B8C53EE266FQ34466689-5841E76B-30A2-41DF-B0CB-A8E6DA441610Q35138392-8C216C36-CF11-4896-A404-D7BD9FF25535Q35547835-B48198BE-05CB-473F-B583-8646794EE10EQ35665977-EE9ABE9A-7F4B-4332-A7F6-7927DA3E025AQ35916866-0315446C-D588-4D5A-8E16-C0332C699140Q36013337-052959B6-1514-42AB-BE9A-F316EFD1B140Q36084937-262B801D-9609-466C-BD8B-640339110A8CQ36151103-5A5D881C-2B62-4ACD-8401-2AF15618ED57Q36501032-5CD44033-5FA5-4015-B0EE-763F1468378FQ36506593-C641EC8B-D01D-402D-8F4D-63A4DFF46B63Q36594210-CE2DC892-281F-460A-8005-2BCE3DDA96CDQ36596126-5B09039D-D2B7-4141-A7F5-6E1C6DC1991FQ36947652-FB644462-1FA6-4723-A2DD-DFD9D5C9600CQ37378094-62266D5B-225E-4E19-A165-979B806B1F26Q37630032-F1E970A4-0C63-4976-905B-2D8A471904D4Q37885790-4AA83BF1-16FA-4BE0-A41F-E82A838BAE8CQ38031830-121DC0F7-061A-4520-98CD-04376516693AQ38055722-91A63A6B-D470-4FB0-B61E-818012B73548Q38115131-2C5587B2-54E3-4B1A-931E-4D2C1D35B212Q38166991-224C1328-F07A-46DE-A28B-37CB56E28E76Q38264660-4FC42341-B5EE-4BAB-9FE3-927113F2BB71Q38285600-229C2CE2-BBA6-401D-B664-D309905069EFQ38302223-24719C79-D33D-4440-8A79-683DBCD5BAD3Q38512329-08A2FE55-9A9F-47F3-9A4D-0DEACC52F9D3Q38542592-4AD5DA0A-2702-403F-B790-282D87A30662Q38555291-E1AC6A45-B2A0-4302-A491-EEF93882E534Q38657993-413660ED-E95C-490C-968A-F37132430BCCQ38661777-82B8CD15-6E91-492D-8BC6-176957E69405Q38692149-29B99280-0B94-4184-A7F9-9B954C51FA46Q38827889-62EB6EAA-9E55-4BE9-B22C-C28A28FB6F2BQ38855759-9BBBC6A6-812F-4B37-A1F4-60755B6AE3EAQ38890533-71EF0AD3-5A9D-4ACB-9BFA-F35429B4C6E9
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rik J Lories
@ast
Rik J Lories
@en
Rik J Lories
@es
Rik J Lories
@nl
Rik J Lories
@sl
type
label
Rik J Lories
@ast
Rik J Lories
@en
Rik J Lories
@es
Rik J Lories
@nl
Rik J Lories
@sl
altLabel
Rik Lories
@en
prefLabel
Rik J Lories
@ast
Rik J Lories
@en
Rik J Lories
@es
Rik J Lories
@nl
Rik J Lories
@sl
P1053
T-2196-2017
P106
P21
P31
P3829
P496
0000-0002-5986-3092
P569
2000-01-01T00:00:00Z